Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to -$274.9 million.

  • Syndax Pharmaceuticals' Free Cash Flow fell 13.18% to -$70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$310.9 million, marking a year-over-year decrease of 20.09%. This contributed to the annual value of -$274.9 million for FY2024, which is 71.17% down from last year.
  • Syndax Pharmaceuticals' Free Cash Flow amounted to -$274.9 million in FY2024, which was down 71.17% from -$160.6 million recorded in FY2023.
  • Syndax Pharmaceuticals' 5-year Free Cash Flow high stood at $29.0 million for FY2021, and its period low was -$274.9 million during FY2024.
  • For the 3-year period, Syndax Pharmaceuticals' Free Cash Flow averaged around -$189.7 million, with its median value being -$160.6 million (2023).
  • In the last 5 years, Syndax Pharmaceuticals' Free Cash Flow surged by 140.70% in 2021 and then crashed by 560.92% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Free Cash Flow (Yearly) stood at -$71.3 million in 2020, then surged by 140.70% to $29.0 million in 2021, then tumbled by 560.92% to -$133.7 million in 2022, then decreased by 20.14% to -$160.6 million in 2023, then slumped by 71.17% to -$274.9 million in 2024.